KB Asset Management announced on the 16th that its 'RISE Bio Top10 Active ETF' ranks first in returns among domestic bio active ETFs.
According to fund evaluator FnGuide, as of the 13th of this month, RISE Bio Top10 Active posted returns of 9.47%, 14.18%, 37.14%, and 14.69% for the past one month, three months, six months, and year-to-date periods, respectively. This represents the highest performance among the five bio active ETFs listed on domestic stock markets.
RISE Bio Top10 Active is a product that focuses investment on 'pure biotech' companies, considered the core growth driver of Korea's bio industry. The fund is characterized by a concentrated portfolio of approximately 20 stocks and an expanded KOSDAQ weighting of about 92%, increasing exposure to pure biotech companies centered on new drug platforms. Pure biotech refers to bio companies that, unlike traditional pharmaceutical or medical device firms, gain corporate value recognition through clinical achievements and technology exports based on their proprietary drug candidates and platform technologies.
The government has recently been pushing to expand funding to innovative industries through various programs including the National Growth Fund, Integrated Managed Account (IMA), and Business Development Company (BDC). The bio industry, in particular, is expected to directly benefit from policy fund inflows as a representative sector with significant market capitalization weight in the KOSDAQ market.
Yook Dong-hwi, Head of ETF Product Marketing at KB Asset Management, said, "RISE Bio Top10 Active's top ranking in returns proves that our differentiated management strategy focused on pure biotech has delivered results in the market," adding, "We will continue to select and invest in high-growth bio companies centered on technology exports and clinical momentum."
